Newsletter - October 26, 2017
Compounding Pharmacy Openly Flouts FDA Regulations
This week a San Diego based compounding pharmacy, Imprimis, announced that it would compound copies of an approved drug product sold by Allergan at a significantly reduced cost. The same company had last year announced that it would compound copies of Daraprim, another FDA approved drug, also to reduce prices. Read More
FDA’s Tacit Encouragement of Interchangeability of Biosimilars
This week FDA released several new pages on its website to “better inform physicians about biosimilars through education about these potentially cost-saving options”, tacitly encouraging physicians to prescribe biosimilars over the innovator biologics. The interchangeability of biosimilar versions of biologics with the reference drug is a hotly contested milestone by the developers of biosimilar products. Read More
Compounding Pharmacy Openly Flouts FDA Regulations
This week a San Diego based compounding pharmacy, Imprimis, announced that it would compound copies of an approved drug product sold by Allergan at a significantly reduced cost. The same company had last year announced that it would compound copies of Daraprim, another FDA approved drug, also to reduce prices. Read More
FDA’s Tacit Encouragement of Interchangeability of Biosimilars
This week FDA released several new pages on its website to “better inform physicians about biosimilars through education about these potentially cost-saving options”, tacitly encouraging physicians to prescribe biosimilars over the innovator biologics. The interchangeability of biosimilar versions of biologics with the reference drug is a hotly contested milestone by the developers of biosimilar products. Read More